ASCO 2025 – Astellas's new Claudin18.2 interest
Evopoint reveals intriguing but opaque first-in-human data for XNW27011.
BioNTech turns $800m into $1.5bn-plus
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
ASCO 2025 – Lilly makes a folate foray against Genmab
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
ASCO 2025 – J&J takes another prostate cancer shot
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
ASCO 2025 – Astra "looked at" patritumab but passed
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.
ASCO 2025 – Dizal goes after the BTK leaders
DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.
ASCO 2025 – BioNTech’s latest Claudin6 effort falls short
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
